Improving The Long-term Quality Of Life For Preterm Children
Funder
National Health and Medical Research Council
Funding Amount
$638,517.00
Summary
My vision is to improve the long-term quality of life of preterm children (<37 weeks’ gestation), with a specific focus on those born very preterm (VP; <32 weeks’ gestation). To achieve this goal my research has two broad and related aims: 1) Determine the neurological and socio-environmental mechanisms leading to impairments in preterm children; and 2) Develop and assess the efficacy of perinatal and early intervention programs for preterm children.
Intermittent Preventive Treatment In Pregnancy With Sulphadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine To Reduce Adverse Pregnancy Outcomes And Prevent Malaria In Papua New Guinea: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,938,453.00
Summary
Millions of pregnancies are complicated by malaria worldwide. Monthly sulphadoxine-pyrimethamine (SP) treatments, the current treatment strategy, no longer protects from malaria but improves birth outcomes through non-malarial effects. Dihydroartemisinin-piperaquine clears malaria but babies are smaller compared to women who received SP. A clinical trial of their combination has potential to substantially improve health outcomes for women and babies in Papua New Guinea and beyond.
I am a molecular biologist-uterine biologist-placentalogist. My research focuses on the regulation of the dramatic uterine tissue remodelling during the establishment of pregnancy and placental development, and on the ultimate impact of uterine factors on
Centre For Clinical Research Excellence In Newborn Medicine
Funder
National Health and Medical Research Council
Funding Amount
$2,519,475.00
Summary
The Centre for Clinical Research Excellence in Newborn Medicine will study adverse outcomes for the brains and lungs of newborn babies; it will establish how often these occur in different types of babies (ranging from very premature babies, through to those born on time), investigate the different causes, develop treatments to either prevent or treat the adverse outcomes, determine the long-term consequences into adulthood, and continually re-evaluate the effectiveness of the various treatment ....The Centre for Clinical Research Excellence in Newborn Medicine will study adverse outcomes for the brains and lungs of newborn babies; it will establish how often these occur in different types of babies (ranging from very premature babies, through to those born on time), investigate the different causes, develop treatments to either prevent or treat the adverse outcomes, determine the long-term consequences into adulthood, and continually re-evaluate the effectiveness of the various treatment strategies designed to improve the health outcomes for newborn babies.Read moreRead less
Premature babies often need assistance to breathe but this can injure the lung and lead to abnormal lung development and long-term lung disease. We have recently identified 3 factors that we believe are fundamental to initiating this abnormal lung development. We will demonstrate that these 3 factors mediate abnormal lung development following lung injury at birth. This information can then be used to reduce the incidence and severity of chronic lung disease of the newborn.
I am a psychologist whose research program aims to improve the long-term well-being for children born very small or immature. My research focuses on 1) determining the nature and severity of cognitive and behavioural problems faced by children born very small-immature, 2) investigating how these problems are associated with brain injury and alterations to brain development, and 3) assessing the effectiveness of clinical interventions which aim to reduce complications and enhance development.
Determining The Impacts Of Epigenetic Modifying Drugs On Germline Programming And Offspring Health
Funder
National Health and Medical Research Council
Funding Amount
$863,918.00
Summary
New drugs have been developed that inhibit specific enzymes that regulate epigenetic pathways in cells. These pathways significantly affect growth and development in offspring and may represent a risk to future children of patients taking the drug. This project will determine these risks and provide data for developing clinical guidelines for safe use of the drugs.